Chemotherapy of Patients with Recurrent Head and Neck Cancer

  • Richard H. Wheeler
Part of the Cancer Treatment and Research book series (CTAR, volume 52)


The majority of cancers of the upper aerodigestive tract are epithelial in origin and epidermoid in histology. With over 40,000 cases diagnosed each year, these malignancies rank eighth in incidence and comprise 4.2% of all malignancies seen annually in the United States [1]. As a group they occur more frequently than the leukemias, the lymphomas, cancer of the stomach, pancreas and melanoma. They represent 6.1% of the cancers occurring in males, and 2.4% of those seen in women. Approximately 30% of these patients will recur and die of their malignancy.


Clin Oncol Neck Cancer Hypertonic Saline Squamous Cell Cancer Advanced Head 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Silverberg E, Lubera JA: Cancer statistics, 1988, Ca 38:3–20, 1989.Google Scholar
  2. 2.
    Strong EW: Preoperative radiation and radical neck dissection. Surg Clin North 49:271–276, 1969.Google Scholar
  3. 3.
    Probert JC, Thompson RW, Bagshaw MA: Patterns of spread of distant metastases in head and neck cancer. Cancer 33:127–133, 1974.PubMedGoogle Scholar
  4. 4.
    Cachin Y, Eschwege F: Combination of radiotherapy and surgery in the treatment of head and neck cancers. Cancer Treat Rev 2:177–191, 1975.PubMedGoogle Scholar
  5. 5.
    Jesse RH, Fletcher GH: Treatment of the neck in patients with squamous cell carcinoma of the head and neck. Cancer 39:868–872, 1977.PubMedGoogle Scholar
  6. 6.
    Martin SA, Marks JE, Lee JY, et al.: Carcinoma of the pyriform sinus: predictor of TNM relapse and survival. Cancer 46:1974–1981, 1980.PubMedGoogle Scholar
  7. 7.
    Bush SE, Bagshaw MA: Carcinoma of the paranasal sinuses. Cancer 50:154–158, 1982.PubMedGoogle Scholar
  8. 8.
    Perez CA, Purdy JA, Breaux SR, et al: Carcinoma of the tonsillar fossa. Cancer 50:2314–2322, 1982.PubMedGoogle Scholar
  9. 9.
    Tong D, Laramore GE, Griffin TW, et al.: Carcinoma of the tonsillar region. Cancer 49:2009–2014, 1982.PubMedGoogle Scholar
  10. 10.
    Kotwall C, Sako K, Razack MS: Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg 154:439–442, 1987.PubMedGoogle Scholar
  11. 11.
    Schechter GL, Kalafsky JT: Cancer of the hypopharynx and cervical esophagus: management concepts. Oncology 2:17–24, 1988.PubMedGoogle Scholar
  12. 12.
    Brown B, Barnes L, Mazariegos J, et al.: Prognostic factors in mobile tongue and floor of mouth carcinoma. Cancer 64:1195–1202, 1989.PubMedGoogle Scholar
  13. 13.
    Foote RL, Buskirk SJ, Stanley RJ, et al.: Patterns of failure after total laryngectomy for glottic carcinoma. Cancer 64:143–149, 1989.PubMedGoogle Scholar
  14. 14.
    Wang ZH, Million RR, Mendenhall WM, et al.: Treatment with preoperative irradiation and surgery of squamous cell carcinoma of the head and neck. Cancer 64:32–38, 1989.PubMedGoogle Scholar
  15. 15.
    Snyderman NL, Johnson JT, Schramm VL, et al.: Extracapsular spread of carcinoma in cervical lymph nodes: impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer 56:1597–1599, 1985.PubMedGoogle Scholar
  16. 16.
    Haplan AS, Caldarelli DD, Chacho MS, et al.: Retrospective DNA analysis of head and neck squamous cell carcinoma. Arch Otolaryngol Head and Neck Surg 112:1159–1162, 1986.Google Scholar
  17. 17.
    De Braud F, Ensley JF, Hassan M, et al.: Prospective correlation of clinical outcome in patients with advanced, resectable squamous cell carcinomas of the head and neck (SCCHN) with DNA ploidy from fresh specimens. Proc Amer Assoc Cancer Res 30:1046, 1989.Google Scholar
  18. 18.
    Levendag P, Sessions R, Vikram B, et al.: The problem of neck relapse in early stage supraglottic larynx cancer. Cancer 63:345–348, 1989.PubMedGoogle Scholar
  19. 19.
    Martial VA, Hanley JA, Ydrach A, et al.: Tolerance of surgery after radical radiotherapy of carcinoma of the oropharynx. Cancer 46:1910–1912, 1980.Google Scholar
  20. 20.
    Wheeler RH, Baker SR, Liepman MK, Ensminger WD: Intensive sequential chemotherapy with bleomycin, Oncovin, mitomycin C, and methotrexate followed by adriamycin, cisplatin, and cyclophosphamide in squamous cell cancer of the head and neck. Med and Pediatr Oncol 11:12–19, 1983.Google Scholar
  21. 21.
    Randolph VL, Vallejo A, Spiro RH, et al.: Combination therapy of advanced head and neck cancer. Cancer 41:460–467, 1978.PubMedGoogle Scholar
  22. 22.
    Amer MH, Al-Sarraf M, Vaitkevicius VK: Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43:2202–2206, 1979.PubMedGoogle Scholar
  23. 23.
    Bertino JR, Boston B, Capizzi RL: The role of chemotherapy in the management of cancer of the head and neck: A review. Cancer 36:752–758, 1975.PubMedGoogle Scholar
  24. 24.
    Mead GM, Jacobs C: Changing role of chemotherapy in the treatment of head and neck cancer. Am J Med 75:582–595, 1982.Google Scholar
  25. 25.
    Ensley J, Maciorowski Z, Hassan M, et al.: Prospective correlation of flow cytometry (FCM) DNA parameters (DNA index and % SPF) and cytotoxic response in previously untreated patients with advanced squamous cell cancers of the head and neck. Proc Amer Assoc Cancer Res 29:105, 1988.Google Scholar
  26. 26.
    Carter SK: The chemotherapy of head and neck cancer. Sem Oncol 4:413–429, 1977.Google Scholar
  27. 27.
    DeConti RC, Schoenfeld D: A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 48:1061–1072, 1981.PubMedGoogle Scholar
  28. 28.
    Hong WK, Schaefer S, Issell B, et al.: A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52:206–210, 1983.PubMedGoogle Scholar
  29. 29.
    Grose WE, Lehane DE, Dixon DO, et al.: Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep 69:577–581, 1985.PubMedGoogle Scholar
  30. 30.
    Vogl SE, Schoenfeld DA, Kaplan BH, et al.: A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56:432–442, 1985.PubMedGoogle Scholar
  31. 31.
    Kirkwood JM, Canellos GP, Ervin TJ, et al.: Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs weekly high dose methotrexate—leucovorin in patients with advanced squamous carcinoma of the head and neck: A safe new effective regimen. Cancer 47:2414–2421, 1981.PubMedGoogle Scholar
  32. 32.
    Woods RL, Fox RM, Tattersal MHN: Methotrexate treatment of advanced head and neck cancers: A dose response evaluation. Cancer Treat Rep 65(Suppl):155–159, 1981.PubMedGoogle Scholar
  33. 33.
    Taylor SG, McGuire WP, Hauck WW, et al.: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 2:1006–1011, 1984.PubMedGoogle Scholar
  34. 34.
    Pizzorno G, Chang YM, McGuire JJ, Bertino JR: Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res 49:5275–5280, 1989.PubMedGoogle Scholar
  35. 35.
    Lippman AJ, Helson C, Helson L, Krakoff IH: Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother. Rep. 57:191–200, 1973.PubMedGoogle Scholar
  36. 36.
    Higby DJ, Wallace J, Holland JF: Cis-diamminedichloroplatinum (NSC-119875). A phase I study. Cancer Chemother Rep 57:459–463, 1973.PubMedGoogle Scholar
  37. 37.
    Talley RW, O’Bryan RM, Gutterman JU, et al.: Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)- Phase I clinical study. Cancer Chemother Rep 57:465–471, 1973.PubMedGoogle Scholar
  38. 38.
    Hayes DM, Cvitkovic E, Golbey RB, et al.: High-dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381, 1977.PubMedGoogle Scholar
  39. 39.
    Gralla RJ, Itri LM, Pisko SE, et al.: Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909, 1981.PubMedGoogle Scholar
  40. 40.
    Kris MG, Gralla RJ, Clark RA, et al.: Consecutive dose-finding trials adding lorazepam to the combination of meloclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257–1262, 1985.PubMedGoogle Scholar
  41. 41.
    Loehrer PJ, Einhorn LH: Cisplatin. Ann Int Med 100:704–713, 1984.PubMedGoogle Scholar
  42. 42.
    Jacobs C, Meyers F, Hendickson C, et al.: A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group Study. Cancer 52:1563–1569, 1983.PubMedGoogle Scholar
  43. 43.
    Veronesi A, Zagonel V, Trielli U, et al.: High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study. J Clin Oncol 3:1105–1108, 1985.PubMedGoogle Scholar
  44. 44.
    Panettiere FJ, Lehane D, Fletcher WS, et al.: Cis-platinum therapy of previously treated head and neck cancer. The Southwest Oncology Group’s two-dose-per-month outpatient regimen. Med Pediatr Oncol 8:221–225, 1980.PubMedGoogle Scholar
  45. 45.
    Bonomi P, Blessing JA, Stehman FB, et al.: Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 3:1079–1085, 1985.PubMedGoogle Scholar
  46. 46.
    Litterst CL: Alterations in the toxicity of cis-dichlorodiammine-platinum-II and in tissue localization of platinum as a function of Na Cl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61:99–108, 1981.PubMedGoogle Scholar
  47. 47.
    Earhart RH, Martin PA, Tutsch KD, et al.: Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 43:1187–1194, 1983.PubMedGoogle Scholar
  48. 48.
    Ozols RF, Corden BJ, Jacob J, et al.: High-dose cisplatin in hypertonic saline. Ann Int Med 100:19–24, 1984.PubMedGoogle Scholar
  49. 49.
    Blumenreich MS, Woodcock TM, Jones M, et al.: High-dose cisplatin in patients with advanced malignancies. Cancer 55:1118–1122, 1985.PubMedGoogle Scholar
  50. 50.
    Forastiere AA, Takasugi BJ, Baker SR, et al.: High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19:155–158, 1987.PubMedGoogle Scholar
  51. 51.
    Bajorin D, Bosl GJ, Fun R: Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 5:1589–1593, 1987.PubMedGoogle Scholar
  52. 52.
    Havlin KA, Kuhn JG, Myers JW, et al.: High-dose cisplatin for locally advanced or metastatic head and neck cancer: A phase II pilot study. Cancer 63:423–427, 1989.PubMedGoogle Scholar
  53. 53.
    Gandara DR, De Gregorio MW, Wold H, et al.: High-dose cisplatin in hypertonic saline: Reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group pilot study in non-small-cell lung cancer. J Clin Oncol 4:1787–1793, 1986.PubMedGoogle Scholar
  54. 54.
    Wheeler RH, Stephens S, Ostroy F: A phase I reappraisal of bolus cisplatin with urinary chloruresis. Proc Amer Assoc Cancer Res 27:171, 1986.Google Scholar
  55. 55.
    Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol 3:1373–1378, 1985.PubMedGoogle Scholar
  56. 56.
    Wilding G, Caruso R, Lawrence TS, et al.: Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 3:1683–1689, 1985.PubMedGoogle Scholar
  57. 57.
    Wheeler RH, Salter M, Stephens S, et al.: Simultaneous therapy with high-dose cisplatin and radiation for unresectable squamous cell cancer of the head and neck: A phase I–II study. NCI Monogr 6:339–341, 1988.PubMedGoogle Scholar
  58. 58.
    Howell SB, Taetle R: The effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) nephrotoxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64:611–616, 1980.PubMedGoogle Scholar
  59. 59.
    Ishizawa M, Taniguchi S, Baba T: Protection by sodium thiosulfate and thiourea against lethal toxicity of cis-diamminedichloroplatinum(II) in bacteria and mice. Japan J Pharmacol 31:883–889, 1981.Google Scholar
  60. 60.
    Allan SG, Smyth JF, Hay FG, et al.: Protective effect of sodium-2-mercaptoethanesulfonate on the gastroentestinal toxicity and lethality of cis-diamminedichloroplatinum. Cancer Res 46:3569–3573, 1986.PubMedGoogle Scholar
  61. 61.
    Pjeifle CE, Howell SB, Felthouse RD, et al.: High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 3:237–244, 1985.Google Scholar
  62. 62.
    Markman M, Cleary S, Pfiefle CE, Howell SB: High-dose intracavitary cisplatin with intravenous thiosulfate. Cancer 56:2364–2368, 1985.PubMedGoogle Scholar
  63. 63.
    Yuhas JM, Culo F: Selective inhibition of the nephrotoxicity of cisplatinum without altering its antitumor effectiveness. Cancer Treat Rep 64:57–64, 1980.PubMedGoogle Scholar
  64. 64.
    Glover D, Glick JH, Weiber C, et al.: Phase I trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 10:1781–1784, 1984.PubMedGoogle Scholar
  65. 65.
    Glover D, Glick JH, Weiber C, et al.: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574–578, 1987.PubMedGoogle Scholar
  66. 66.
    Borch RF, Pleasants ME: Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci USA 76:6611–6614, 1979.PubMedGoogle Scholar
  67. 67.
    Evans RG, Wheatley C, Engle C, et al.: Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate. Cancer Res 44:3686–3690, 1984.PubMedGoogle Scholar
  68. 68.
    Bodenner DL, Deglon PC, Keng PC, et al.: Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by dielhyldithiocarbamate. Cancer Res 46:2751–2755, 1986.PubMedGoogle Scholar
  69. 69.
    Schmalbach TK, Borch RF: Myeloprotective effect of diethyldithiocarbamate treatment following l,3-bis(2-chloroethyl)-i-nitrosourea, adriamycin or mitomycin c in mice. Cancer Res 49:2574–2577, 1989.PubMedGoogle Scholar
  70. 70.
    Paredes J, Hong WK, Felder TB, et al.: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6:955–962, 1988.PubMedGoogle Scholar
  71. 71.
    Wheeler RH, Liepman MK, Baker SR, et al.: Bleomycin, vincristine and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma. Cancer Treat Rep 64:943–949, 1980.PubMedGoogle Scholar
  72. 72.
    Kish J, Drelichman A, Jacobs J, et al.: Clinical trials of cis-platinum and 5-fluorouracil infusion as initial treatment of advanced squamous carcinoma of the head and neck. Cancer Treat Rep 66:471–474, 1982.PubMedGoogle Scholar
  73. 73.
    Tapazoglou E, Kish J, Ensley J, Al-Sarraf M: The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57:1105–1109, 1986.PubMedGoogle Scholar
  74. 74.
    Kish, JA, Ensley JF, Jacobs J, et al.: A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740–2744, 1985.PubMedGoogle Scholar
  75. 75.
    Cobleigh MA, Hill JH, Gaflagher PA, et al.: A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck. Cancer 56:2573–2575, 1985.PubMedGoogle Scholar
  76. 76.
    Speer RJ, Ridgway H, Hall LM, et al.: Coordination complexes of platinum as antitumor agents. Cancer Chemother Rep 59:629–641, 1975.PubMedGoogle Scholar
  77. 77.
    Muggia FM: Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 16(Suppl 5):7–13, 1989.PubMedGoogle Scholar
  78. 78.
    Ozols RF: Optimal dosing with carboplatin. Semin Oncol 16(Suppl 5): 14–18, 1989.PubMedGoogle Scholar
  79. 79.
    Alberts DS, Mason-Leddil N: Carboplatin in the treatment of ovarian cancer. Semin Oncol 16(Suppl 5): 19–26, 1989.PubMedGoogle Scholar
  80. 80.
    Eisenberger M, Van Echo D, Aisner J: Carboplatin: The experience in head and neck cancer. Semin Oncol 16(Suppl 5):34–41, 1989.PubMedGoogle Scholar
  81. 81.
    Forastiere A, Metch B, Keppen M, et al.: Randomized comparison of cisplatin (CDDP) + 5-fluorouracil (5-FU) vs. carboplatin (CBP) + 5-FU vs. methotrexate (MTX) in advanced squamous cell carcinoma of the head and neck. Proc ASCO 8:168. (And Personal Communication), 1989.Google Scholar
  82. 82.
    Livingston RB, Einhorn LH, Bodey GP, et al.: COMB (cyclophosphamide, oncovin, methyl-CCNU, and bleomycin): a four drug combination in solid tumors. Cancer 36:327–332, 1975.PubMedGoogle Scholar
  83. 83.
    Wittes RE, Spiro RH, Shah J, et al.: Chemotherapy of head and neck cancer: combination treatment with cyclophosphamide, adriamycin, methotrexate, and bleomycin. Med and Pediatr Oncol 3:301–309, 1977.Google Scholar
  84. 84.
    Huang AT, Lucas VS, Baughn SG, Cole TB: A trial of outpatient chemotherapy for recurrent head and neck tumors. Cancer 45:2038–2041, 1980.PubMedGoogle Scholar
  85. 85.
    Cortes EP, Kalra J, Amen VC, et al.: Chemotherapy for head and neck cancer relapsing after radiotherapy. Cancer 47:1966–1970, 1981.PubMedGoogle Scholar
  86. 86.
    Price LA, Hill BT, Calvert AH, et al.: Kinetically-based multiple drug treatment for advanced head and neck cancer. Br Med J 3:10–11, 1975.PubMedGoogle Scholar
  87. 87.
    Tannock I, Sutherland D, Osoba D: Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer. Cancer 49:1358–1361, 1982.PubMedGoogle Scholar
  88. 88.
    Livingston RB, Bodey GP, Gottlieb JA, Frei E: Kinetic scheduling of vincristine (NSC-67574) and bleomycin (NSC-125066) in patients with lung cancer and other malignant tumors. Cancer Chemother Rep 57:219–224, 1973.PubMedGoogle Scholar
  89. 89.
    Amer MH, Igbicki RM, Vaitkevicius VK, Al-Sarraf M: Combination chemotherapy with cis-diamminedichloroplatinum, Oncovin, and bleomycin (COB) in advanced head and neck cancer. Phase II. Cancer 45:217–223, 1980.PubMedGoogle Scholar
  90. 90.
    Perry DJ, Weltz MD, Brown AW, et al.: Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 50:2257–2260, 1982.PubMedGoogle Scholar
  91. 91.
    Creagan ET, Fleming TR, Edmonson JH, et al.: Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum(II) in the treatment of patients with advanced head and neck cancer. Cancer 47:240–244, 1981.PubMedGoogle Scholar
  92. 92.
    Creagan ET, Fleming TR, Edmonson JH, et al.: Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum(II): Preliminary assessment of a one-day vs. three-day drug regimen. Cancer 47:2549–2551, 1981.PubMedGoogle Scholar
  93. 93.
    Kish JA, Weaver A, Jacobs J, et al.: Cisplatin and 5-fluorouracil infusion in patients with recurrent and dissiminated epidermoid cancer of the head and neck. Cancer 53:1819–1824, 1984.PubMedGoogle Scholar
  94. 94.
    Rowland KM, Taylor SG, Spiers ASD, et al.: Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 70:461–464, 1986.PubMedGoogle Scholar
  95. 95.
    Merlano M, Tatarek R, Grimaldi A, et al.: Phase I–II trial with cisplatin and 5-FU in recurrent head and neck cancer: An effective outpatient schedule. Cancer Treat Rep 69:961–964, 1985.PubMedGoogle Scholar
  96. 96.
    Amrien PC, Weitzman SA: Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 3:1632–1639, 1985.Google Scholar
  97. 97.
    Vokes EE, Choi KE, Schilsky RL, et al.: Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618–626, 1988.PubMedGoogle Scholar
  98. 98.
    Vogl SE, and Kaplan BH: Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule. Cancer 44:26–31, 1979.PubMedGoogle Scholar
  99. 99.
    Frei III E: Combination Chemotherapy: Presidential address. Cancer Res 32:2593–2607, 1972.PubMedGoogle Scholar
  100. 100.
    Martin DS, Stoffi RL, Sawyer RC, Young CW: Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 69:421–423, 1985.PubMedGoogle Scholar
  101. 101.
    Wheeler RH, Clauw DJ, O’Toole TE, Ensminger WD: Cytokinetic evaluation of the four-drug combination of bleomycin, vincristine, mitomycin C, and methotrexate (BOMM) in cultured Burkitt’s lymphoma cells and human bone marrow. Cancer 50:1993–1999, 1982.PubMedGoogle Scholar
  102. 102.
    Livingston RB, Einhorn LH, Burgess MA, Gottlieb JA,: Sequential combination chemotherapy for advanced recurrent, squamous carcinoma of the head and neck. Cancer Treat Rep 60:103–105, 1976.PubMedGoogle Scholar
  103. 103.
    Browman GP, Levine MN, Goodyear MD: Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial. J Clin Oncol 6:963–968, 1988.PubMedGoogle Scholar
  104. 104.
    Schabel FM Jr, Trader MW, Laster WE Jr, et al.: Cis-dichlorodiammineplatinum II combination chemotherapy and cross resistance studies of tumors of mice. Cancer Treat Rep 63:1459–1473, 1979.PubMedGoogle Scholar
  105. 105.
    Creagan E, Ingle J, Schutt A, et al.: A phase II study of cis-diamminedichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasms. Head and Neck Surg 6:1020–1023, 1984.Google Scholar
  106. 106.
    Davis S, Kessler W: Randomized comparison of cis-diamminedichloroplatinum versus cis-diammindichloroplatinum, methotrexate, and bleomycin in recurrent squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 3:57–59, 1979.PubMedGoogle Scholar
  107. 107.
    Drelichman A, Cummings G, Al-Sarraf M: A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck. Cancer 52:399–403, 1983.PubMedGoogle Scholar
  108. 108.
    Morton RP, Rugman F, Dorman EB, et al.: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 15:283–289, 1985.PubMedGoogle Scholar
  109. 109.
    Williams SD, Valez-Garcia E, Essessee I, et al.: Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 57:18–23, 1986.PubMedGoogle Scholar
  110. 110.
    Campbell JB, Dorman EB, McCormick M, et al.: A randomized phase III trial of cisplatinum, methotrexate, cisplatin + methotrexate, and cisplatinum + 5-fluorouracil in end-stage head and neck cancer. Acta Otolaryngol 103:519–528, 1987.PubMedGoogle Scholar
  111. 111.
    Cavel M, Cognetti F, Dodion P, et al.: Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60:1173–1177, 1987.Google Scholar
  112. 112.
    Eisenberger M, Krasnow S, Ellenberg S, et al.: A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol 7:1341–1345, 1989.PubMedGoogle Scholar
  113. 113.
    Natale RB, Wheeler RH, Roberts JA: Cisplatin and dichloromethotrexate: A pharmacologically rational combination. NCI Monogr 5:219–223, 1987.PubMedGoogle Scholar
  114. 114.
    Wheeler RH, Natale RB, Roshon SG Baker SR: A phase I–II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck. J Clin Oncol 2:831–835, 1984.PubMedGoogle Scholar
  115. 115.
    Rosowsky A, Wright JE, Cucchi CA, et al.: Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diammine-dichloroplatinum(II). Cancer Res 47:5913–5918, 1987.PubMedGoogle Scholar
  116. 116.
    Taylor SG, Murthy AK, Showel JL, et al.: Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy. Cancer Treat Rep 69:933–939, 1985.PubMedGoogle Scholar
  117. 117.
    Vokes EE, Panje WR, Schilsky RL, et al.: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor prognosis head and neck cancer: a phase I–II study. J Clin Oncol 7:761–768, 1989.PubMedGoogle Scholar
  118. 118.
    Frei E III, Canellos G: Dose: a critical factor in cancer chemotherapy. Am J Med 69:583–594, 1980.Google Scholar
  119. 119.
    Collins JM, Dedrick RL: Pharmacokinetics of anticancer drugs. In: pharmacologic principles of cancer treatment. Chabner B (ed), Philadelphia: WB Saunders, pp 77–99, 1982.Google Scholar
  120. 120.
    Fensmacher J, Gazendam J: Intraarterial infusions of drugs and hyperosomotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 65(Suppl 2):27–38, 1981.Google Scholar
  121. 121.
    Levin VA, Landahl HD, Patlak CS: Drug delivery to CNS tumors. Cancer Treat Rep 65(Suppl 2): 19–26, 1981.PubMedGoogle Scholar
  122. 122.
    Wheeler RH, Ziessman HA, Medvec BR, et al.: Tumor blood flow and systemic shunting in patients receiving, intra-arterial chemotherapy for head and neck cancer. Cancer Res 46:4200–4204, 1986.PubMedGoogle Scholar
  123. 123.
    Bruce WR, Meeker BE, Powers WE, Valeriote FA: Comparison of the dose- and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine and amethopterin. J Natl Cancer Inst 42:1015–1023, 1969.PubMedGoogle Scholar
  124. 124.
    Mellett LB: Considerations in design of optimal therapeutic schedules. In: Pharmacology and the Future of Man. Proceedings of the 5th International Congress in Pharmacology, San Francisco, vol 3, Karger, Basal, pp 332–353, 1973.Google Scholar
  125. 125.
    Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245, 1966.PubMedGoogle Scholar
  126. 126.
    Young RC, Rosenoff SA, Myers CE, et al.: Alterations in DNA synthesis induced by chemotherapeutic agents in vivo: Potential applications to clinical treatment schedules. In: Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells. Drewinko B, Humphrey RM, (eds), Baltimore: Williams & Wilkins, pp 787–809, 1977.Google Scholar
  127. 127.
    Jusko WJ: A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J Pharmacokin Biopharm 1:175–200, 1973.Google Scholar
  128. 128.
    Parlavecchio G: Sul lavaggio antisettico interstizaile dei tessut dolla vie arteriosa. Policlinico (Sez Prat) 6:667–674, 1899.Google Scholar
  129. 129.
    Klopp CT, Alfordd TC, Bateman J, et al.: Fractionated intraarterial cancer chemotherapy with methyl bis amine hydrochloride: A preliminary report. Ann Surg 132:811–832, 1950.PubMedGoogle Scholar
  130. 130.
    Clarkson B, Lawrence W Jr: Perfusion and infusion techniques in cancer chemotherapy. J Clin North Amer 45:689–710, 1961.Google Scholar
  131. 131.
    Johnson RO, Kisken WA, Curreri AR: A report upon arterial infusion with 5-fluorouracil in 100 patients. Surg Gynec Obste 120:530–636, 1965.Google Scholar
  132. 132.
    Bitter KJ: Pharmacokinetic behavior of bleomycin-cobalt-57 with special regard to intraarterial perfusion of the maxillofacial region. Maxillofac Surg 4:226–231, 1976.Google Scholar
  133. 133.
    Szabo G, Kovacs A: Possibilities of enhancing the effectiveness of intraarterial chemotherapy. Int J Oral Surg 9:33–44, 1980.PubMedGoogle Scholar
  134. 134.
    Burkhardt A, Holtje WJ: Effects of intraarterial bleomycin therapy in squamous cell carcinoma of the oral cavity: biopsy and autopsy examination. Maxillofac Surg 3:217–230, 1975.Google Scholar
  135. 135.
    Richard JM, Sancho H: Intraarterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institute Gustave Roussy. Biomedicine 18:429–435, 1973.PubMedGoogle Scholar
  136. 136.
    Ziekle-Temme BC, Stevens KR Jr, Everts EC, et al.: Combined intraarterial chemotherapy radiation therapy and surgery for advanced squamous cell carcinoma of the head and neck. Cancer 45:1527–1532, 1980.Google Scholar
  137. 137.
    Madajewica S, Kanter P, West C, et al.: Plasma, spinal fluid and organ distribution of cisplatinum (DDP) following intravenous (IV) and intracarotid (IC) infusion. Proc Amer Assoc Cancer Res and ASCO 22:176, 1981.Google Scholar
  138. 138.
    Gouyette A, Apehin A, Foka M, Richard JM: Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol 22:257–263, 1986.PubMedGoogle Scholar
  139. 139.
    Lehane DE, Sessions R, Johnson P, et al.: Intraarterial cisplatinum administration for advanced squamous cell carcinoma of the head and neck region. International Head and Neck Oncology Research Conference, Rosslyn, VA, Abstract #2.11, 1980.Google Scholar
  140. 140.
    Goldman HL, Bilbao MK, Rosch J, Dotter CT: Complications of indwelling chemotherapy catheters. Cancer 36:1883–1990, 1975.Google Scholar
  141. 141.
    Helsper JT, DeMoss EV: Regional intraarterial infusion of 5-fluorouracil for cancer. Surgery 56:340–348, 1964.PubMedGoogle Scholar
  142. 142.
    Hanna DC, Gaisford JC, Goldwyn RM: Intraarterial nitrogen mustard for control of pain in head and neck cancer. Am J Surg 106:783–785, 1963.PubMedGoogle Scholar
  143. 143.
    Watkins E Jr, Sullivan RD: Cancer chemotherapy by prolonged arterial infusion. SGO 118(1):3–19, 1964.PubMedGoogle Scholar
  144. 144.
    Baker SR, Wheeler RH, Medvec BR: Surgical aspects of intraarterial therapy of outpatients with head and neck cancer. Otolaryngol—Head Neck Surg 93:192–199, 1985.PubMedGoogle Scholar
  145. 145.
    Baker SR, Wheeler RH, Ziesman H, Medvec BR: Radionuclide localization of intraarterial infusion in head and neck cancer. Cancer Drug Delivery 1:145–156, 1984.PubMedGoogle Scholar
  146. 146.
    Wheeler RH, Baker SR, Medvec BM: Single agent and combination drug regional chemotherapy for head and neck cancer using an implantable infusion pump. Cancer 54:1504–1512, 1984.PubMedGoogle Scholar
  147. 147.
    Forastiere AA, Baker SR, Wheeler RH, Medvec BR: A phase II trial of intra-arterial cisplatin and FUDR in advanced malignancies confined to the head and neck. J Clin Oncol 5:1601–1606, 1987.PubMedGoogle Scholar
  148. 148.
    Ziessman HA, Forastiere AA, Wheeler RH, et al.: The use of a vasoconstrictor to improve tumor blood flow in intra-arterial chemotherapy: A preliminary report. Nuc Med Commun 6:777–786, 1985.Google Scholar
  149. 149.
    Frustaci S, Barzan L, Tumolo S, et al.: Intra-arterial continuous infusion cis-diamminedichloroplatinum in untreated head and neck cancer patients. Cancer 57:1118–1123, 1986.PubMedGoogle Scholar
  150. 150.
    Cheung DK, Regan J, Savin M, et al.: A pilot study of intraarterial chemotherapy with cisplatin in locally advanced head and neck cancers. Cancer 61:903–908, 1988.PubMedGoogle Scholar
  151. 151.
    Jacobs C: Editorial: adjuvant chemotherapy for head and neck cancer. J Clin Oncol 7:823–826, 1989.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Richard H. Wheeler

There are no affiliations available

Personalised recommendations